Related Experiment Video
Updated: Sep 13, 2025
A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors
Published on: October 30, 2016
Vaccinia Virus-A Swiss Army Knife Against Cancer
Marcin Stawowczyk1, Yanqi Ye1, Nanhai G Chen1
1ViroMissile, Inc., 505 Coast Blvd South, Suite 208, La Jolla, CA 92037, USA.
Abstract:
Despite significant advances in cancer therapy, the prognosis for patients with advanced, disseminated disease remains poor. This underscores the urgent need for novel treatments that not only eliminate tumor cells effectively but also stimulate a strong, durable anti-cancer immune response. Among emerging strategies, oncolytic viruses have shown exceptional promise due to their selective cytotoxicity and their ability to activate T cell-mediated immune responses. In this review, we focus on the vaccinia virus (VACV), a member of the Poxviridae family, which has emerged as a leading candidate in modern oncolytic immunotherapy. We examine the virus's properties that enable it to evade antiviral defenses and serve as a versatile, potent oncolytic agent. Furthermore, we explore its interactions with various components of the immune system and how these contribute to the induction of a robust T cell-driven response. Finally, we assess current efforts to harness VACV for the treatment of various cancer types and highlight future directions where its application is most likely to succeed. Overall, our goal is to present VACV as a powerful and broadly applicable platform with the potential to transform the landscape of oncology.
Insights
Vaccinia virus (VACV) shows promise as an oncolytic immunotherapy. This review explores how VACV effectively targets cancer cells and stimulates a potent anti-cancer immune response, offering a new therapeutic platform.
Area of Science:
- Oncology
- Virology
- Immunotherapy
Background:
- Advanced cancer necessitates novel treatments beyond conventional therapies.
- Oncolytic viruses offer a promising strategy by selectively killing cancer cells and activating immune responses.
Purpose of the Study:
- To review the potential of vaccinia virus (VACV) as an oncolytic immunotherapy agent.
- To examine VACV's mechanisms for evading immune defenses and its interactions with the immune system.
- To assess current applications and future directions for VACV in cancer treatment.
Main Methods:
- Review of scientific literature on vaccinia virus and oncolytic virotherapy.
- Analysis of VACV's biological properties and immunomodulatory effects.
- Evaluation of clinical and preclinical studies involving VACV for cancer therapy.
Main Results:
- VACV demonstrates selective tumor cell lysis and potent immune stimulation.
- VACV possesses properties that allow it to overcome host antiviral defenses.
- VACV has shown versatility in preclinical models across various cancer types.
Conclusions:
- VACV is a potent and versatile oncolytic virus with significant potential in cancer immunotherapy.
- Harnessing VACV offers a promising avenue for developing durable, T cell-mediated anti-cancer immunity.
- Further research and clinical trials are warranted to optimize VACV-based cancer therapies.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:51Mechanisms of Retrovirus-induced Cancers
01:27Tumor Immunotherapy
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
01:51Vaccinations